Pharmacologic Treatment of Chronic Insomnia Disorder in Older Adults
Quetiapine is generally not an appropriate or safe pharmacologic option for insomnia in older adults because available evidence of efficacy is limited and adverse effects align with known risks of antipsychotics in older adults. VA/DoD insomnia/OSA clinical practice guideline (2025), [1]
First-line treatment is cognitive behavioral therapy for insomnia (CBT-I). [2], [1]
Quetiapine Appropriateness and Safety in Older Adults With Insomnia
Evidence for quetiapine in insomnia is insufficient for efficacy determination. VA/DoD insomnia/OSA clinical practice guideline (2025)
VA/DoD recommends against antipsychotic drugs for chronic insomnia disorder in patients offered pharmacotherapy, reflecting unfavorable benefit–risk. VA/DoD insomnia/OSA clinical practice guideline (2025)
All antipsychotics carry a black-box warning for increased mortality in elderly patients with dementia-related psychosis. VA/DoD insomnia/OSA clinical practice guideline (2025)
VA/DoD also notes age-related harms associated with antipsychotics, including cerebrovascular accident risk, cognitive decline, and mortality risk, consistent with Beers Criteria avoidance in older adults unless specific indications exist. VA/DoD insomnia/OSA clinical practice guideline (2025)
Antipsychotic class adverse effects relevant to insomnia care include sedating and hypotensive effects (anticholinergic effects), and metabolic harms requiring monitoring (hyperglycemia, dyslipidemia, weight gain). VA/DoD insomnia/OSA clinical practice guideline (2025)
Comparative Efficacy: CBT-I, Melatonin, Dual Orexin Receptor Antagonists vs Quetiapine
CBT-I is recommended as initial treatment for chronic insomnia disorder in adults. [2]
AASM’s pharmacologic guideline supports dual orexin receptor antagonists for insomnia, including suvorexant for sleep maintenance insomnia (weak recommendation). AASM pharmacologic treatment of insomnia guideline (2017)
Direct efficacy comparisons between quetiapine and CBT-I or dual orexin receptor antagonists are limited by the small, short-duration evidence base for quetiapine insomnia. VA/DoD insomnia/OSA clinical practice guideline (2025)
Comparative Adverse-Effect Profile: Quetiapine vs First-Line Options
Quetiapine
Quetiapine’s adverse-effect profile in older adults is dominated by antipsychotic class risks, including:
- Black-box mortality warning in dementia-related psychosis. VA/DoD insomnia/OSA clinical practice guideline (2025)
- Increased risk of cerebrovascular events, cognitive decline, and mortality in older adults with dementia, consistent with Beers Criteria avoidance. VA/DoD insomnia/OSA clinical practice guideline (2025)
- Sedation and hypotension from anticholinergic effects. VA/DoD insomnia/OSA clinical practice guideline (2025)
- Metabolic harms requiring monitoring (hyperglycemia, dyslipidemia, weight gain). VA/DoD insomnia/OSA clinical practice guideline (2025)
Melatonin
AASM suggests clinicians not use melatonin for sleep onset or sleep maintenance insomnia in adults (weak recommendation; very low certainty). AASM pharmacologic treatment of insomnia guideline (2017)
VA/DoD similarly recommends against melatonin for chronic insomnia disorder (weak against). VA/DoD insomnia/OSA clinical practice guideline (2025)
Dual orexin receptor antagonists (DORAs)
AASM supports suvorexant for sleep maintenance insomnia (weak recommendation), and broadly supports other FDA-approved non-benzodiazepine hypnotics across sleep onset and maintenance indications. AASM pharmacologic treatment of insomnia guideline (2017)
Comparative meta-analytic evidence for DORAs (daridorexant vs lemborexant) indicates differences in efficacy and adverse-event rates:
- Daridorexant was associated with higher rates of treatment-emergent adverse events versus placebo in one systematic review/meta-analysis comparison (RR reported in the source). [3]
- Lemborexant showed no statistically significant difference in overall treatment-emergent adverse events versus placebo in the same analysis. [3]
Initiation Thresholds and Treatment Sequence
CBT-I is recommended as initial therapy for chronic insomnia disorder. [2]
When pharmacotherapy is chosen for chronic insomnia disorder, VA/DoD recommends against antipsychotic drugs. VA/DoD insomnia/OSA clinical practice guideline (2025)
When pharmacotherapy is chosen, DORAs are guideline-supported options, including AASM support for suvorexant in sleep maintenance insomnia. AASM pharmacologic treatment of insomnia guideline (2017)
Common Pitfalls to Avoid in Older Adults
Treating insomnia with antipsychotics is a key avoidable pitfall because efficacy evidence is limited and antipsychotic class harms are clinically relevant in older adults. VA/DoD insomnia/OSA clinical practice guideline (2025)
Using melatonin as a stand-alone treatment is also a pitfall relative to guideline recommendations, because both AASM and VA/DoD advise against it for chronic insomnia disorder in adults. AASM pharmacologic treatment of insomnia guideline (2017), VA/DoD insomnia/OSA clinical practice guideline (2025)
Practical Comparative Conclusion for Decision-Making
Quetiapine is not an appropriate or guideline-aligned pharmacologic treatment for insomnia in older adults due to limited efficacy evidence and antipsychotic class safety risks. VA/DoD insomnia/OSA clinical practice guideline (2025)
CBT-I is the recommended initial strategy for chronic insomnia disorder. [2]
Melatonin is guideline-disfavored for chronic insomnia disorder. AASM pharmacologic treatment of insomnia guideline (2017), VA/DoD insomnia/OSA clinical practice guideline (2025)
Dual orexin receptor antagonists are guideline-supported pharmacologic options when insomnia symptoms warrant medication, with adverse effects that are generally less dominated by antipsychotic-specific harms than quetiapine. AASM pharmacologic treatment of insomnia guideline (2017), [3]